Efficacy and safety of combination acitretin and pioglitazone therapy in patients with moderate to severe chronic plaque-type psoriasis: A randomized, double-blind, placebo-controlled clinical trial

Archives of Dermatology

Volumn 145, Issue 4, 2009, Pages 387-393

  Mittal, Rajan ^a   Malhotra, Samir ^b   Pandhi, Promila ^a   Kaur, Inderjeet ^b   Dogra, Sunil ^b  

^a Departments of Pharmacology   (India)

^b POSTGRADUATE INSTITUTE OF MEDICAL EDUCATION AND RESEARCH   (India)

Author keywords

[No Author keywords available]

Indexed keywords

ETRETIN; PIOGLITAZONE; PLACEBO;

ACUTE HEART INFARCTION; ADULT; AGED; ARTHRALGIA; ARTICLE; BLURRED VISION; BODY MASS; CHEILITIS; CHRONIC DISEASE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CORONARY ARTERY DILATATION; DIABETES MELLITUS; DISEASE SEVERITY; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG SAFETY; ERYTHEMA; FEMALE; GASTRITIS; HUMAN; HYPERLIPIDEMIA; KIDNEY FUNCTION; LIVER FUNCTION; MALE; MYALGIA; PRIORITY JOURNAL; PRURITUS; PSORIASIS VULGARIS; RANDOMIZED CONTROLLED TRIAL; RHINITIS; SCORING SYSTEM; SIDE EFFECT; TERTIARY HEALTH CARE; THIRST; TREATMENT DURATION; TREATMENT OUTCOME; UNSPECIFIED SIDE EFFECT; WEIGHT GAIN; XEROSTOMIA;

ACITRETIN; ADOLESCENT; ADULT; AGED; DERMATOLOGIC AGENTS; DOUBLE-BLIND METHOD; DRUG THERAPY, COMBINATION; FEMALE; HUMANS; MALE; MIDDLE AGED; PSORIASIS; THIAZOLIDINEDIONES; YOUNG ADULT;

EID: 65349091931     PISSN: 0003987X     EISSN: 15383652     Source Type: Journal    
DOI: 10.1001/archdermatol.2009.5     Document Type: Article

References (35)

1. Nalcli L, Svensson A, Diepgen T, et al; European Dermato-Epiclemiology Network. Randomized clinical trials for psoriasis 1977-2000: the EDEN survey. J Invest Dermatol. 2003;120(5):738-741.
2. Finlay AY, Coles EC. The effect of severe psoriasis on the quality of life of 369 patients. Br J Dermatol. 1995;132(2):236-244.
3. Rapp SR, Feldman SR, Exum ML, Fleischer AB Jr, Reboussin DM. Psoriasis causes as much disability as other major medical diseases. J Am Acad Dermatol. 1999; 41(3, pt1):401-407.
4. Griffiths CE, Barker JN. Pathogenesis and clinical features of psoriasis. Lancet. 2007;370(9583):263-271.
5. Lebwohl M, Menter A, Koo J, Feldman SR. Combination therapy to treat moderate to severe psoriasis. J Am Acad Dermatol. 2004;50(3):416-430.
6. Lebwohl M, Ali S. Treatment of psoriasis, II: systemic therapies. J Am Acad Dermatol. 2001 ;45(5):649-661.
7. Yamauchi PS, Rizk D, Lowe NJ. Retinoid therapy for psoriasis. Dermatol Clin. 2004;22(4):467-476.
8. Geiger JM, Czarnetzki BM. Acitretin (Ro 10-1670, etretin): overall evaluation of clinical studies. Dermatologica. 1988;176(4):182-190.
9. Kragballe K, Jansen CT, Geiger JM, et al. A double-blind comparison of acitretin and etretinate in the treatment of severe psoriasis: results of a Nordic multicentre study. Acta Derm Venereol. 1989;69(1):35-40.
10. Olsen EA, Weed WW, Meyer CJ, Cobo LM. A double-blind, placebo-controlled trial of acitretin for the treatment of psoriasis. J Am Acad Dermatol. 1989;21 (4, pt1):681-686.
11. Pearce DJ, Klinger S, Ziel KK, Murad EJ, Rowell R, Feldman SR. Low-dose acitretin is associated with fewer adverse events than high-dose acitretin in the treatment of psoriasis. Arch Dermatol. 2006;142(8):1000-1004.
12. Tanew A, Guggenbichler A, Honigsmann H, Geiger JM, Fritsch P. Photochemotherapy for severe psoriasis without or in combination with acitretin: a randomized, double-blind comparison study. J Am Acad Dermatol. 1991 ;25(4):682-684.
13. Koo J. Systemic sequential therapy of psoriasis: a new paradigm for improved therapeutic results. J Am Acad Dermatol. 1999;41(3, pt 2):S25-S28.
14. van de Kerkhof PC, Cambazard F, Hutchinson PE, et al. The effect of addition of calcipotriol ointment (50 ug/g) to acitretin therapy in psoriasis. Br J Dermatol. 1998;138(1):84-89.
15. Waugh J, Keating GM, Plosker GL, Easthope S, Robinson DM. Pioglitazone: a review of its use in type 2 diabetes mellitus. Drugs. 2006;66(1):85-109.
16. Ellis CN, Varani J, Fisher GJ, et al. Troglitazone improves psoriasis and normal-izes models of proliferative skin disease: ligands for peroxisome proliferatorsactivated receptor-gamma inhibit keratinocytes proliferation. Arch Dermatol. 2000; 136(5) :609-616.
17. Demerjian M, Man MQ, Choi EH, et al. Topical treatment with thiazolidinecliones, activators of peroxisome proliferator-activated receptor-gamma, normalizes epidermal homeostasis in a murine hyperproliferative disease model. Exp Dermatol. 2006;15(3):154-160.
18. Ricote M, Li AC, Willson TM, Kelly CJ, Glass CK. The peroxisome proliferativeactivated receptor-gamma is a negative regulator of macrophage activation. Nature. 1998;391(6662):79-82.
19. Buckingham RE. Thiazolidinediones: pleiotropic drugs with potent antiinflammatory properties for tissue protection. Hepatol Res. 2005;33(2):167-170.
20. Marx N, Wohrle J, Nusser T, et al. Pioglitazone reduces neointima volume after coronary stentimplantation: a randomized, placebo-controlled, double-blind trial in nondiabetic patients. Circulation. 2005;112(18):2792-2798.
21. Pershadsingh HA, Sproul JA, Benjamin E, Finnegan J, Amin NM. Treatment of psoriasis with troglitazone therapy. Arch Dermatol. 1998;134(10):1304- 1305.
22. Robertshaw H, Friedmann PS. Pioglitazone: a promising therapy for psoriasis. Br J Dermatol. 2005;152(1):189-191.
23. Shafiq N, Malhotra S, Pandhi P, et al. Pilot trial: pioglitazone versus placebo in patients with plaque psoriasis (the P6). Int J Dermatol. 2005;44(4):328-333.
24. Brauchli YB, Jick SS, Curtin F, Meier CR. Association between use of thiazolidinediones or other oral antidiabetics and psoriasis: a population based casecontrol study. J Am Acad Dermatol. 2008;58(3):421-429.
25. Malhotra S, Bansal D, Shafiq N, Pandhi P, Kumar B. Potential therapeutic role of peroxisome proliferators activated receptor-gamma agonists in psoriasis. Expert Opin Pharmacother. 2005;6(9):1455-1461.
26. Marks R, Barton SP, Shuttleworth D, Finlay AY. Assessment of disease progress in psoriasis. Arch Dermatol. 1989;125(2):235-240.
27. Orfanos CE, Zouboulis CC, Almond-Roesler B, Geilen CC. Current use and future potential role of retinoids in dermatology. Drugs. 1997;53(3):358-388.
28. Saurat JH. Retinoids and psoriasis: novel issues in retinoid pharmacology and implications for psoriasis treatment. J Am Acad Dermatol. 1999;41(3, pt 2): S2-S6.
29. Katz HI, Waalen J, Leach EE. Acitretin in psoriasis: an overview of adverse effects. J Am Acad Dermatol. 1999;41(3, pt 2):S7-S12.
30. Kaye JA, Li L, Jick SS. Incidence of risk factors for myocardial infarction and other vascular diseases in patients with psoriasis. Br J Dermatol. 2008;159 (4):895-902.
31. Soriatane (acitretin) [prescribing information]. Steifel Web site. http://www .soriatane.com/. Accessed May 10, 2006.
32. Ellis CN, Barker JN, Haig AE, Parker CA, Daly S, Jayawardene DA; Avandia Psoriasis Study Group. Placebo response in two long-term randomized psoriasis studies that were negative for rosiglitazone. Am J Clin Dermatol. 2007;8(2): 93-102.
33. Aronoff S, Rosenblatt S, Braithwaite S, Egan JW, Mathisen AL, Schneider RL. Pioglitazone hydrochloride monotherapy improves glycemic control in the treatment of patients with type 2 diabetes: a 96 month randomized placebocontrolled dose-response study: the Pioglitazone 001 Study Group. Diabetes Care. 2000;23(11):1605-1611.
34. ParulkarAA, Pendergrass ML, Granda-Ayala R, Lee TR, FonsecaVA. Nonhypoglycemic effects of thiazolidinediones. Ann Intern Med. 2001 ;134(1):61-71.
35. HenselerT, Christophers E. Disease concomitance in psoriasis. J Am Acad Dermatol. 1995;32(6):982-986.